M05.079, Felty's syndrome, unspecified ankle and footICD-10-CM
No Prior Auth Required
Covered without prior authorization by at least one policy, though another does not cover it (medium confidence)
CGS-J15-L39427, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
J15
CGS-J18-L39427, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
J18
A59536, Billing and Coding: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
J5
A59434, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
J5
WPS-J5-L39481, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
J5
A52423, Billing and Coding: Infliximab and biosimilars
J6
NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
J6
NGS-J6-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
J6
A59101, Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars
J6
A58893, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
J6
WPS-J8-L39481, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
J8
A57657, Billing and Coding: Sedimentation Rate, Erythrocyte
J9
FIRST_COAST-L34021, Sedimentation Rate, Erythrocyte
J9
A59764, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
J9
NOVITAS-JH-L35062, Biomarkers Overview
JH
NOVITAS-JH-L39063, Pharmacogenomics Testing
JH
NGS-JK-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
JK
NGS-JK-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
JK
NOVITAS-JL-L39063, Pharmacogenomics Testing
JL
NOVITAS-JL-L35062, Biomarkers Overview
JL
Ask Backwork about documentation requirements, denial risks, or coverage in your state.